SCHEMBL22494765

SCHEMBL22494765

C[C@@H]1CCCC[C@H]1c1cnc(NC(=O)[C@H]2C[C@H](NC#N)C2)s1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ CCNE1 P24864 4/20 0.37
▸ CDK2 P24941 4/20 0.37
▸ CDK5 Q00535 4/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ USP30 Q70CQ3 1/20 0.36
▸ UCHL1 P09936 3/20 0.35
▸ LCK P06239 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MKNK1 Q9BUB5 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ OGA O60502 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22494678 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494654 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494764 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22522973 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494705 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494707 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494680 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22494653 1.00 SMN1; SMN2 (0.45) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22523021 0.86 SMN1; SMN2 (0.49) SMN1; SMN2CCNE1CDK2CDK5RAB9A
SCHEMBL22523008 0.86 SMN1; SMN2 (0.49) SMN1; SMN2CCNE1CDK2CDK5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP claimed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US claimed
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 SMN1; SMN2 88/4885CCNE1 3461/4885CDK2 1919/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 SMN1; SMN2 181/4885CCNE1 2017/4885CDK2 1051/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 SMN1; SMN2 88/4885CCNE1 3461/4885CDK2 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback